28 January 2021 | Views
By the end of 2021, Frost & Sullivan predicts that close to 4.12 billion COVID-19 vaccine doses will be delivered globally to immunise priority target groups
Source credit: Frost & Sullivan
The varying levels of COVID-19 vaccine acceptability range from 90-50% across countries, which further plagues the timeline to reach herd immunity and bring an end to the pandemic.
With Pfizer-BioNTech and Moderna vaccinations underway, low- to middle-income countries placing bets on the successful rollout of the Oxford-AstraZeneca vaccine.
It is estimated that around 18 billion doses will be required to immunise the global population. By the end of 2021, Frost & Sullivan predicts that close to 4.12 billion COVID-19 vaccine doses will be delivered globally to immunise priority target groups, namely healthcare workers, adults above the age of 65, and adults with co-morbidities.
A partnership between the developed and developing economies is required in the prevention, detection, containment, and cure of an infectious disease pandemic.
Key Implications for a Successful Global COVID-19 Vaccine Rollout in 2021:
Unmesh Lal, Industry Principal, Transformational Health Practice, Frost & Sullivan